Company intelligence / Profile preview

HOPO Therapeutics

Berkeley, California, United Stateshopotx.com ↗

Ownership: Private
Development stage: Phase 1

Overview

HOPO‑101 has entered Phase 1 safety studies in humans. Preclinical data show superior efficacy to standard-of-care countermeasures with improved selectivity—removing toxic metals while sparing essential minerals. The company’s approach offers broad potential impact given the global burden of heavy metal poisoning. No FDA-approved products yet.

Therapeutic areas: Other
Modalities: Small molecules (specifically, orally available chelating agents)
Industry: Biotech

Drug pipeline

1 asset

HOPO 14-1

Partnerships

SRI International (conducting Phase I trial)government funding receivedseeking partnerships with physicians/governments/global health nonprofits/investors.

Beyond the preview

Go deeper on HOPO Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HOPO Therapeutics.

Explore the full profile